Pfizer pays record $2.3 billion to settle off-label claims in the US
This article was originally published in SRA
Drug maker Pfizer has agreed to pay a staggering $2.3 billion to the US Department of Justice to resolve criminal and civil liability charges arising from the off-label promotion of four medicines1. The amount, according to the DoJ, is the largest ever in the history of healthcare fraud settlements.
You may also be interested in...
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.